Eli Lilly’s LillyDirect platform is partnering with Walmart to let patients pick up prescriptions for its GLP-1 drug Zepbound at Walmart pharmacies, expanding access beyond home delivery.
October has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Eli Lilly, CommonSpirit Health and HLM Venture Partners welcomed new executives. There were also layoffs at organizations including Genentech and Jefferson Health.
Sheila Bond, MD, talked about the latest trends regarding integration of AI in healthcare.
The FDA clinical hold covers two Phase 3 studies for nexiguran ziclumeran, or nex-z, an experimental gene-editing therapy for transthyretin amyloidosis. Nex-z uses the CRISPR gene-editing technology to inactivate the gene that codes for the protein driving this rare disease.
We must work together across the care continuum to establish both local and network-trusted identity data management capabilities that can unify patient data across fragmented data silos at both the database layer and the front-end digital and physical access layer.
It’s not the flashiest technologies or rapid-speed AI breakthroughs that can do it. It’s the technologies laser-focused on the unglamorous but all-consuming coordination problems that suck up medical staff’s time, stress them out, and compromise patient care.
The 2025 Benefits Sentiment Index is based on a survey of 120 benefit consultants to self-insured employers and is sponsored by Quantum Health.
How Apella leverages technology to increase OR efficiency.
Acquisition talks for Metsera that played out this year culminated in an agreement with Pfizer, which agreed to buy the obesity drug developer for $4.9 billion. Novo Nordisk, a finalist in that pursuit, is positioning itself as a deal spoiler with a new unsolicited offer that shells out much more upfront cash.
With federal PBM reform stalled, states like California are stepping up with laws like SB 41 to boost transparency and lower drug costs.
During Reuters’ Total Health conference in Chicago, four healthcare leaders shared the strategies they believe will help fortify the workforce for the future.
The AI Index in RCM highlights the findings of our survey of 125 medical billing executives who offered insights and feedback on RCM tech.
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
The cybersecurity process is something you need to invest effort in now. Here's some insight on conducting a security risk analysis that is impactful for the whole life of a medical device or medical device software.
Equity has to be built into the deployment strategy from day one, not treated as a future retrofit. That means prioritizing inclusion not only in the data but in the delivery, and recognizing that inclusive deployment is the foundation for inclusive datasets.
MedCity News Editor-in-Chief Arundhati Parmar and Reporter Marissa Plescia interviewed health tech executives at HLTH 2025.
Generic drugs don’t need lengthy clinical trials to support a submission seeking FDA approval. The regulator now proposes ending this testing requirement for biosimilars, products that reference complex biologic medicines.
HealthTap and Samsung Health have partnered to offer virtual primary and urgent care within the Samsung Health app.